CO5170482A1 - Neuropeptidos y antagonistas utiles en el tratamiento de trastornos alimenticios y enfer- medades cardiovasculares - Google Patents
Neuropeptidos y antagonistas utiles en el tratamiento de trastornos alimenticios y enfer- medades cardiovascularesInfo
- Publication number
- CO5170482A1 CO5170482A1 CO99081405A CO99081405A CO5170482A1 CO 5170482 A1 CO5170482 A1 CO 5170482A1 CO 99081405 A CO99081405 A CO 99081405A CO 99081405 A CO99081405 A CO 99081405A CO 5170482 A1 CO5170482 A1 CO 5170482A1
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- medades
- neuropeptides
- antagonists
- cardiovascular
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 108090000189 Neuropeptides Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 101710151321 Melanostatin Proteins 0.000 abstract 2
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un método para inhibir o aliviar una condición patológica o un trastorno fisiológico en un mamífero, que se caracteriza por, o se asocia con, el neuropéptido Y, que comprende administrar a un mamífero que necesita de dicho tratamiento, una cantidad que inhibe al neuropéptido Y, del compuesto de la fórmula :<EMI FILE="99081405_1" ID="1" IMF=JPEG >en que R se selecciona entre -N(C2H5)2, -CH3 y -C-O-C2H5; o una sal farmacéuticamente aceptable de éste.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11739599P | 1999-01-27 | 1999-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5170482A1 true CO5170482A1 (es) | 2002-06-27 |
Family
ID=22372692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99081405A CO5170482A1 (es) | 1999-01-27 | 1999-12-29 | Neuropeptidos y antagonistas utiles en el tratamiento de trastornos alimenticios y enfer- medades cardiovasculares |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6197822B1 (es) |
| EP (1) | EP1027891B1 (es) |
| JP (1) | JP3502586B2 (es) |
| KR (1) | KR100372989B1 (es) |
| AT (1) | ATE285759T1 (es) |
| AU (1) | AU1352000A (es) |
| CA (1) | CA2296970C (es) |
| CO (1) | CO5170482A1 (es) |
| DE (1) | DE69922918T2 (es) |
| DK (1) | DK1027891T3 (es) |
| ES (1) | ES2234218T3 (es) |
| HU (1) | HUP0000307A2 (es) |
| IL (1) | IL134157A0 (es) |
| NZ (1) | NZ502518A (es) |
| PE (1) | PE20001416A1 (es) |
| PT (1) | PT1027891E (es) |
| ZA (1) | ZA200000313B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6407120B1 (en) * | 1999-02-18 | 2002-06-18 | Pfizer Inc. | Neuropeptide Y antagonists |
| US20070141156A1 (en) * | 2005-12-21 | 2007-06-21 | Uri Herzberg | Compositions and methods for preventing or reducing postoperative ileus and gastric stasis |
| US8129359B2 (en) | 2004-06-04 | 2012-03-06 | Ethicon, Inc. | Composition and method for treating post-surgical pain |
| US8377906B2 (en) | 2004-06-04 | 2013-02-19 | Ethicon, Inc. | Compositions and methods for preventing or reducing postoperative ileus and gastric stasis |
| JP5167275B2 (ja) | 2007-01-04 | 2013-03-21 | エスケー ケミカルズ カンパニー リミテッド | 明るさに優れたポリアリーレンスルフィド樹脂の製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| AU692977B2 (en) * | 1994-11-07 | 1998-06-18 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
| EP0759441A3 (en) * | 1995-06-30 | 1999-06-30 | Eli Lilly And Company | Methods of treating neuropeptide Y-associated conditions |
| US6048900A (en) * | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
| EP1033366A3 (en) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Amide derivatives useful as Neuropeptide Y (NPY) antagonists |
-
1999
- 1999-12-23 DK DK99310483T patent/DK1027891T3/da active
- 1999-12-23 ES ES99310483T patent/ES2234218T3/es not_active Expired - Lifetime
- 1999-12-23 DE DE69922918T patent/DE69922918T2/de not_active Expired - Fee Related
- 1999-12-23 AT AT99310483T patent/ATE285759T1/de not_active IP Right Cessation
- 1999-12-23 PT PT99310483T patent/PT1027891E/pt unknown
- 1999-12-23 EP EP99310483A patent/EP1027891B1/en not_active Expired - Lifetime
- 1999-12-29 CO CO99081405A patent/CO5170482A1/es not_active Application Discontinuation
-
2000
- 2000-01-20 IL IL13415700A patent/IL134157A0/xx unknown
- 2000-01-24 AU AU13520/00A patent/AU1352000A/en not_active Abandoned
- 2000-01-25 ZA ZA200000313A patent/ZA200000313B/xx unknown
- 2000-01-25 US US09/491,293 patent/US6197822B1/en not_active Expired - Fee Related
- 2000-01-25 CA CA002296970A patent/CA2296970C/en not_active Expired - Fee Related
- 2000-01-26 PE PE2000000055A patent/PE20001416A1/es not_active Application Discontinuation
- 2000-01-26 NZ NZ502518A patent/NZ502518A/en unknown
- 2000-01-26 KR KR10-2000-0003550A patent/KR100372989B1/ko not_active IP Right Cessation
- 2000-01-26 HU HU0000307A patent/HUP0000307A2/hu unknown
- 2000-01-27 JP JP2000018938A patent/JP3502586B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000212077A (ja) | 2000-08-02 |
| CA2296970A1 (en) | 2000-07-27 |
| JP3502586B2 (ja) | 2004-03-02 |
| ZA200000313B (en) | 2001-07-25 |
| DE69922918D1 (de) | 2005-02-03 |
| EP1027891B1 (en) | 2004-12-29 |
| EP1027891A2 (en) | 2000-08-16 |
| US6197822B1 (en) | 2001-03-06 |
| DK1027891T3 (da) | 2005-05-09 |
| ES2234218T3 (es) | 2005-06-16 |
| ATE285759T1 (de) | 2005-01-15 |
| EP1027891A3 (en) | 2002-07-17 |
| PT1027891E (pt) | 2005-04-29 |
| NZ502518A (en) | 2001-06-29 |
| KR20000053607A (ko) | 2000-08-25 |
| IL134157A0 (en) | 2001-04-30 |
| AU1352000A (en) | 2000-08-03 |
| PE20001416A1 (es) | 2000-12-18 |
| CA2296970C (en) | 2004-11-02 |
| HU0000307D0 (en) | 2000-03-28 |
| DE69922918T2 (de) | 2006-03-30 |
| HUP0000307A2 (hu) | 2000-12-28 |
| KR100372989B1 (ko) | 2003-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0110420A (pt) | Agonistas muscarìnicos | |
| EA200700232A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| CO5690131A1 (es) | Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento de transtornos del snc | |
| AP2001002291A0 (en) | Novel method of treatment. | |
| EA200601799A1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
| SE9800550D0 (sv) | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof | |
| KR950016746A (ko) | 비-펩티드 타키키닌 수용체 길항물질 | |
| MXPA02012434A (es) | Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii. | |
| AR019246A1 (es) | Agonistas de receptores de 5-ht1 y metoclopramida para el tratamiento de la migrana. | |
| KR930003912A (ko) | 울혈성 심장 마비 치료법 | |
| ATE357923T1 (de) | Behandlung der osteoporose | |
| ES2176600T3 (es) | Derivado de la propiofenona y procedimientos para su preparacion. | |
| CO5251404A1 (es) | Compuestos antibioticos de azalida | |
| CO5280060A1 (es) | Aminoacidos biciclicos como agentes farmaceuticos | |
| EA200200194A1 (ru) | Антагонисты хемокинного рецептора и способы их применения | |
| DE69328186D1 (de) | Zusammensetzung zur behandlung der parkinson-krankheit | |
| KR950016725A (ko) | 폐 고혈압성 질병을 억제하는 방법 | |
| RU94045278A (ru) | Применение 2-фенил-3-ароилбензтиофенов для ингибирования вазомоторных симптомов и сопутствующих психологических нарушений, ассоциированных с постклимактерическим синдромом | |
| EA200200132A1 (ru) | СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ | |
| ES2119094T3 (es) | Inhibicion de la hemorragia uterina disfuncional. | |
| CO5271724A1 (es) | Uso de agonistas de prostaglandinas para tratar la disfuncion erectil o la impotencia | |
| CA2498210A1 (en) | Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia | |
| CO5170482A1 (es) | Neuropeptidos y antagonistas utiles en el tratamiento de trastornos alimenticios y enfer- medades cardiovasculares | |
| EA200400530A1 (ru) | Перекрестно-сшитые антибиотики "гликопептид-цефалоспорин" | |
| RU94044356A (ru) | Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |